PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Celecoxib

Drugs in development · updated 30 October 2026

Celecoxib: clinical trials and development status

Other names and codes: Celebrex Capsule, Elyxyb, Vyscoxa, Onsenal

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 17 October 2003

As of 30 October 2026 Celecoxib is in 38 active clinical trials (recruiting or ongoing, phases I–III) for 49 diseases. The most advanced phase is III.

38Active trials
IIIMost advanced phase
49Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Celecoxib and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 49 diseases.

DiseaseMost advanced phaseActive trialsReference trial
InflammationIII1NCT05644301
Major depressive disorderIII1NCT05644301
Prostatic NeoplasmsII–III1NCT00268476
Colorectal neoplasmII4NCT07809893
MedulloblastomaII3NCT01356290
CarcinomaII2NCT06997068
EpendymomaII2NCT01356290
NeoplasmII2NCT02574728
NeuroblastomaII2NCT02574728
PinealomaII2NCT02574728
Rhabdoid tumorII2NCT02574728
Turcot syndromeII2NCT06903858
Acute respiratory distress syndromeII1NCT04488081
Brain NeoplasmsII1NCT02574728
Cerebral hemorrhageII1NCT05434065
CholangiocarcinomaI–II1NCT07632235
Colonic neoplasmII1NCT03026140
COVID-19II1NCT04488081
DiabetesII1NCT07139405
Diffuse large B-cell lymphomaII1NCT07494565
EpilepsyII1NCT05637086
Esophageal squamous cell carcinomaII1NCT07049185
Ewing sarcomaII1NCT02574728
Germ cell and embryonal neoplasmsII1NCT02574728
Head and neck neoplasmsII1NCT06997068
Hepatocellular carcinomaII1NCT07174570
Hypopharyngeal NeoplasmsII1NCT06997068
Langerhans-cell histiocytosisII1NCT02574728
Laryngeal neoplasmII1NCT06997068
Mouth NeoplasmsII1NCT06997068

Everything on Celecoxib

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch